Skip to main content

    Jefferies raises Minerva Neurosciences (NERV) rating to Buy

    GNG Research Market News

    By GNG Research

    Minerva Neurosciences Inc (NERV) moved from Hold to Buy at Jefferies on August 14, 2026, following an upgrade.

    Among one firm active over the past 90 days, one holds a bullish rating. As of October 30, 2026, five analysts place the consensus mean at $10.54, the median at $10.20 and the range at $7.07 to $14.70.

    For Q4 FY2026, analysts expect EPS of -$0.14 and revenue of $0. The next earnings report is scheduled for March 9, 2027.